CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $1.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +13.95%. A quarter ago, it was expected that this company would post a loss of $0.4 per share when it actually produced a loss of $0.38, delivering a surprise of +5%.Over the last four quarters, the company has surpassed ...

Exagen Inc. (XGN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -46.15%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.18, delivering no surprise.Over the last four quarters, the company has surpassed consensus ...

AdaptHealth Corp. (AHCO) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.33%. A quarter ago, it was expected that this company would post earnings of $0.15 per share when it actually produced earnings of $0.01, delivering a surprise of -93.33%.Over the last four quarters, the compa ...

InfuSystems Holdings, Inc. (INFU) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +37.50%. A quarter ago, it was expected that this company would post earnings of $0.03 per share when it actually produced earnings of $0.12, delivering a surprise of +300%.Over the last four quarters, t ...

公司概况 - 公司是医疗产品行业的重要参与者，专注于为睡眠呼吸暂停、慢性阻塞性肺病和其他呼吸系统疾病提供创新解决方案 [1] - 公司以强劲的财务表现和持续超越市场预期的能力而闻名 [1] - 主要竞争对手包括飞利浦和费雪派克医疗保健等医疗器械公司 [1] 盈利表现 - 2025年10月30日报告的每股收益为2.55美元，超过2.51美元的预期，较去年同期2.20美元显著改善 [2] - 当季盈利超出预期2.41% [2] - 在过去四个季度中，公司持续超越市场共识的每股收益预期，显示出强大的财务管理能力 [2] 收入表现 - 截至2025年9月的季度收入达到13.4亿美元，超过13.3亿美元的预期 [3] - 收入较去年同期增长9.1% [3] - 收入亦超过扎克斯共识预期的13.2亿美元，实现0.94%的正向意外 [3] - 持续的收入增长突显了公司获取市场份额和推动销售的能力 [3] 运营指标 - 毛利率改善290个基点至61.5%，非公认会计准则毛利率上升至62.0% [4] - 运营收入增长15%，非公认会计准则运营收入增长19% [4] - 运营指标的改善反映了公司高效的成本管理和卓越的运营能力 [4] 财务健康状况 - 债务权益比率约为0.15，表明债务水平相对于权益较低 [5] - 流动比率约为3.44，突显了公司用短期资产覆盖短期负债的能力 [5] - 市盈率为26.38，结合其他财务指标，展示了公司稳固的财务状况和未来增长潜力 [5]

Stryker (SYK) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.14 per share. This compares to earnings of $2.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.59%. A quarter ago, it was expected that this medical device maker would post earnings of $3.06 per share when it actually produced earnings of $3.13, delivering a surprise of +2.29%.Over the last four quarters, the comp ...

季度业绩表现 - 公司季度每股收益为2.55美元，超出市场预期的2.49美元，同比增长16% [1] - 季度营收达到13.4亿美元，超出市场预期0.94%，同比增长9.8% [2] - 公司在过去四个季度中均超出每股收益和营收的市场预期 [2] 近期股价与市场比较 - 公司股价年初至今上涨约10.9%，同期标普500指数上涨17.2% [3] - 公司股票当前获Zacks评级为第三级（持有），预计短期内表现将与市场同步 [6] 未来业绩预期 - 市场对下一季度的共识预期为每股收益2.65美元，营收13.9亿美元 [7] - 对本财年的共识预期为每股收益10.75美元，营收55.6亿美元 [7] 行业背景 - 公司所属的医疗器械行业在Zacks行业排名中处于后41%位置 [8] - 同行业公司InfuSystems Holdings预计季度每股收益为0.08美元，与去年同期持平，营收预计为3720万美元，同比增长5.3% [9][10]

Capricor Therapeutics (CAPR) shares soared 12% in the last trading session to close at $6.92. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 14.3% loss over the past four weeks.The sharp rise in CAPR shares can be attributed to the company’s recent regulatory progress and growing optimism around upcoming clinical milestones. Management’s prior update confirming FDA alignment on trial endpoints has strengthened expectations for a ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share. This compares to earnings of $2.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.74%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $1.93 per share when it actually produced earnings of $2.61, delivering a surprise of +35. ...

AtriCure (ATRC) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +90.91%. A quarter ago, it was expected that this medical device maker would post a loss of $0.15 per share when it actually produced a loss of $0.02, delivering a surprise of +86.67%.Over the last four quarters, the company ha ...